title: Hydrophilic acrylic intraocular lens as a drug-delivery system: Pilot study.
abstract: OBJECTIVE
  To evaluate the ability of a hydrophilic acrylic intraocular lens (IOL) to serve as a drug-delivery system for commercially available gatifloxacin and moxifloxacin.
  
  
  METHODS
  David J. Apple, MD, Laboratories for Ophthalmic Devices Research, John A. Moran Eye Center, University of Utah, Salt Lake City, Utah, USA.
  
  
  METHODS
  Hydrophilic acrylic IOLs (C-flex, Rayner Ltd.), presoaked for 24 hours in commercially available solutions of gatifloxacin (Zymar) or moxifloxacin (Vigamox), were implanted in the capsular bag of 6 rabbits for a total of 12 eyes (6 in each group). Aqueous humor samples were taken 2, 4, and 6 hours after implantation. One rabbit served as a control and had nonpresoaked C-flex IOLs implanted. At the end of the operation, 1 drop of Vigamox was applied to the right eye and 1 drop of Zymar was applied to the left eye of the control rabbit.
  
  
  RESULTS
  High concentrations of both antibiotics were found in all the samples of the eyes implanted with the presoaked IOLs. The concentrations of the antibiotics decreased over time, but even the 6-hour sample concentrations were markedly higher than the concentrations found in the control rabbit after 4 hours.
  
  
  CONCLUSIONS
  The results suggest that the Rayner C-flex IOL can be effective as a drug-delivery system for fourth-generation fluoroquinolones.
authors.affiliation: David J Apple, MD, Laboratories for Ophthalmic Devices Research, John A. Moran Eye Center, Department of Ophthalmology and Visual Sciences, University of Utah, Salt Lake City, Utah 84132, USA. guy.kleinmann@hsc.utah.edu
authors.forename: Guy
authors.initials: G
authors.lastname: Kleinmann
authors.forename: David J
authors.initials: DJ
authors.lastname: Apple
authors.forename: Jesse
authors.initials: J
authors.lastname: Chew
authors.forename: Scott
authors.initials: S
authors.lastname: Stevens
authors.forename: Brian
authors.initials: B
authors.lastname: Hunter
authors.forename: Scott
authors.initials: S
authors.lastname: Larson
authors.forename: Nick
authors.initials: N
authors.lastname: Mamalis
authors.forename: Randall J
authors.initials: RJ
authors.lastname: Olson
mesh_terms: D000180:Acrylic Resins; D000818:Animals; D000890:Anti-Infective Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001082:Aqueous Humor / Q000378:metabolism; D001372:Aza Compounds / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001682:Biological Availability; D016503:Drug Delivery Systems; D024841:Fluoroquinolones / Q000008:administration & dosage* / Q000493:pharmacokinetics; D000077734:Gatifloxacin; D019654:Lens Implantation, Intraocular; D007910:Lenses, Intraocular; D008297:Male; D000077266:Moxifloxacin; D010865:Pilot Projects; D011804:Quinolines / Q000008:administration & dosage* / Q000493:pharmacokinetics; D011817:Rabbits
chemical_list: D000180:Acrylic Resins; D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077734:Gatifloxacin; D000077266:Moxifloxacin